<SEC-DOCUMENT>0001193125-14-008154.txt : 20140110
<SEC-HEADER>0001193125-14-008154.hdr.sgml : 20140110
<ACCEPTANCE-DATETIME>20140110172533
ACCESSION NUMBER:		0001193125-14-008154
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140108
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140110
DATE AS OF CHANGE:		20140110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		14522672

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d659029d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): January&nbsp;8, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-21392</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ireland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chief Executive Officer Compensation Terms </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously announced, effective January&nbsp;1, 2014, John F. Thero became President and Chief Executive Officer of Amarin Corporation plc
(the &#147;Company&#148;). On January&nbsp;10, 2014, in connection with such promotion, the Company and Mr.&nbsp;Thero entered into an amended and restated employment agreement (the &#147;Agreement&#148;), which replaces Mr.&nbsp;Thero&#146;s
current employment agreement with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agreement was approved by the Remuneration Committee of the Board of Directors of the
Company (the &#147;Remuneration Committee&#148;) in consultation with an independent compensation consultant. All references to &#147;cause,&#148; &#147;good reason&#148; and &#147;change in control&#148; are as defined in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Agreement, Mr.&nbsp;Thero will serve as President and Chief Executive Officer of the Company and report to the Company&#146;s Board
of Directors. Mr.&nbsp;Thero&#146;s base annual salary will be $500,000, effective January&nbsp;1, 2014. He will also be eligible to receive an annual performance bonus targeted at up to 65% of his base salary, with the actual amount of such bonus,
if any, to be determined by the Board of Directors. Mr.&nbsp;Thero will also be entitled to continue to participate in the benefits and insurance programs generally available to all Company employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agreement provides further that, if Mr.&nbsp;Thero is terminated without cause or quits for good reason, he will be entitled to severance
as follows: continuation of base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq. (commonly known as
&#147;COBRA&#148;); and twelve (12)&nbsp;months of accelerated vesting on all outstanding equity incentive awards to the extent subject to time-based vesting. If Mr.&nbsp;Thero is terminated without cause or he quits for good reason, in either case,
within twenty-four (24)&nbsp;months following a change in control, then he will be entitled to severance as follows: continuation of base salary for eighteen (18)&nbsp;months; continuation of group health plan benefits for up to eighteen
(18)&nbsp;months to the extent authorized by and consistent with COBRA; a lump sum cash payment equal to the full target annual performance bonus for the year during which the termination occurred; and 100% acceleration of vesting on all outstanding
equity incentive awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Agreement is qualified in its entirety by reference to the complete text of the
Agreement, a copy of which is filed as Exhibit 10.1 to this Report and is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to Terms of Incentive Bonus
Program </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As previously disclosed, on December&nbsp;2, 2013, the Remuneration Committee approved a special incentive bonus program
(the &#147;Bonus Program&#148;) for each of John F. Thero, President and Chief Executive Officer; Steven B. Ketchum, Ph.D., President of Research and Development, Senior Vice President; and Joseph T. Kennedy, Senior Vice President, General Counsel.
On January&nbsp;8, 2014, the Remuneration Committee revised the Bonus Program as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Bonus Program, each of these
executive officers will be eligible to receive a one-time, special bonus payment in the amount of: (i)&nbsp;$250,000, in the event the Company&#146;s sNDA for the ANCHOR indication is approved by the FDA on or before December&nbsp;31, 2014; or
(ii)&nbsp;$150,000, in the event the FDA approves the inclusion of the clinical data from the Company&#146;s ANCHOR Phase III clinical trial in the Vascepa label for the current (MARINE) indication on or before December&nbsp;31, 2014; or
(iii)&nbsp;$150,000, in the event the Company successfully secures a declaratory judgment from a court of competent jurisdiction on or before December&nbsp;31, 2014 confirming the Company&#146;s ability to inform physicians of the clinical data from
the Company&#146;s ANCHOR Phase III clinical trial notwithstanding an FDA failure to approve the Company&#146;s sNDA for the ANCHOR indication by December&nbsp;31, 2014. All determinations concerning the above referenced criteria for payment will be
made by the Company in its sole discretion. No other changes to the Bonus Program were made. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement with John Thero, dated as of January 10, 2014</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: January&nbsp;10, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph Kennedy</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Joseph Kennedy</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Senior Vice President, General Counsel</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit&nbsp;Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement between Amarin Corporation plc and John Thero, dated as of January 10, 2014</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d659029dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g659029ex10_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;10, 2014 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John
F. Thero <U> </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Amarin Pharma, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1430 Route 206
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bedminster, NJ 07921 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr.&nbsp;Thero: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of Amarin Corporation plc (the &#147;Company&#148;), I am pleased to confirm the terms of your continued employment with the
Company, effective January&nbsp;10, 2014. The purpose of this letter agreement is to set forth those terms of employment. This letter agreement (the &#147;Agreement&#148;) fully supersedes any prior agreements, understanding or arrangements, whether
oral or written, implied or express, with respect to the terms and conditions of your employment with the Company including, without limitation, your employment agreement with the Company dated December&nbsp;23, 2011, and any other employment
agreement, offer letter or other agreement or understanding relating to compensation, benefits, severance pay or other terms or conditions of employment (collectively, the &#147;Prior Agreements&#148;), provided any agreement you have with the
Company and/or any of its subsidiaries or affiliates related to confidentiality/nondisclosure, noncompetition, nonsolicitation, assignment of inventions and patents, any stock option agreement entered into by you in connection an equity award issued
to you by the Company or its subsidiaries or affiliates and any Deed of Indemnity applicable to you (collectively the &#147;Preserved Agreements&#148;) shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With those understandings, you and the Company agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>Position:</B> Your current position with the Company is President and Chief Executive Officer (&#147;CEO&#148;). You will have such
duties, responsibilities and authorities as determined by the Company&#146;s Board of Directors (the &#147;Board&#148;). This is a full-time position. It is understood and agreed that, while you render services to the Company, you will not engage in
any other employment, consulting or other business activities (whether full-time or part-time) without prior express written consent of the Board. Notwithstanding the foregoing, you may (i)&nbsp;serve on one outside board of directors as long as
such service is disclosed to the Board and (ii)&nbsp;engage in religious, charitable, or other community activities, <I>provided</I> that your services or activities under subsections (i)&nbsp;and (ii)&nbsp;do not interfere or conflict with your
obligations to the Company. In addition to your role as President and CEO, you acknowledge and agree that you may be required, without additional compensation, to perform duties for certain affiliated entities of the Company, including without
limitation Amarin Pharma, Inc., and to accept any reasonable office or position with any such affiliate as the Company&#146;s Board of Directors may require, including, but not limited to, service as an officer or director of any such affiliate.
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr. John Thero </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 10, 2014 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>Salary:</B> The Company will pay you a salary at the annual rate of $500,000, effective
as of January&nbsp;1, 2014, subject to periodic review and adjustment at the discretion of the Company. Currently our policy is to make salary payments semi-monthly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>Bonus:</B> You will be eligible to receive annual performance bonuses. The Company will target the Bonus of up to 65% of your annual
salary rate. The actual bonus is discretionary and will be subject to the Company&#146;s assessment of your performance, as well as business conditions at the Company. The bonus also will be subject to your employment for the full period covered by
the bonus, approval by and adjustment at the discretion of the Company&#146;s Board of Directors or an authorized committee thereof, and the terms of any applicable bonus plan. The Company may also make adjustments in the targeted amount of your
annual performance bonus. Any bonus awarded to you will be paid by March&nbsp;15 of the year following the bonus year to which such bonus relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B>Benefits:</B> You will be eligible to participate in the employee benefits and insurance programs generally made available to its
full-time employees, including health, life, disability and dental insurance. You will be eligible for up to eighteen (18)&nbsp;days of paid time off (&#147;PTO&#148;) per year, which shall accrue on a prorated basis. Other provisions of the
Company&#146;s PTO policy are set forth in the policy itself. You will be reimbursed for all reasonable business expenses you incur while carrying out your duties on behalf of the Company provided such reimbursement shall be conditioned on you
following the Company&#146;s reimbursement policies and claims procedures, including by providing appropriate documentation of such expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B>Stock Options:</B> Except as expressly provided herein, your current equity with the Company shall be governed by the terms of the
Company&#146;s 2002 Stock Option Plan and associated stock option or other stock agreements and/or 2011 Stock Incentive Plan and associated stock option or other stock agreements, as applicable (collectively the &#147;Equity Documents&#148;). You
shall be eligible for additional equity based awards at the discretion of the Company and subject to approval by the Company&#146;s Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B>At-will Employment, Accrued Obligations; Severance: </B>Your employment will continue to be &#147;at will&#148; meaning you or the
Company may terminate it at any time for any or no reason. In the event of the termination of your employment for any reason, the Company shall pay you the Accrued Obligations, defined as (1)&nbsp;your base salary through the date of termination,
(2)&nbsp;an amount equal to the value of your accrued unused PTO days, if any, and (3)&nbsp;the amount of any business expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. In addition to
the Accrued Obligations, in the event the Company terminates your employment without Cause at any time, or you terminate your employment for Good Reason (defined below), or during the twenty-four (24)&nbsp;month period that immediately follows a
Change of Control (the &#147;Post-Change in Control Period&#148;) the Company terminates your employment without Cause or you terminate your employment for Good </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr. John Thero </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 10, 2014 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Reason, the Company shall provide you with the following termination benefits (the &#147;Termination Benefits&#148;), which shall be substantively dependent on the date of the last day of your
employment (the &#147;Date of Termination&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) continuation of your base salary then in effect during the
&#147;Salary Continuation Period&#148; which shall be either: (A)&nbsp;twelve (12)&nbsp;months from the Date of Termination, if the Company terminates your employment without Cause or you terminate your employment for Good Reason and the Date of
Termination occurs at any time outside of the Post-Change in Control Period, or (B)&nbsp;eighteen (18)&nbsp;months from the Date of Termination, if the Company terminates your employment without Cause or you terminate your employment for Good Reason
and, in either case, the Date of Termination occurs during the Post-Change in Control Period. Solely for purposes of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, each Salary Continuation Payment during the Salary Continuation
Period is considered a separate payment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) continuation of group health plan benefits to the extent authorized by and
consistent with 29 U.S.C. &#167; 1161 et seq. (commonly known as &#147;<B>COBRA</B>&#148;), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the date of termination
until the earlier of: (i)&nbsp;the end of the Salary Continuation Period, and (ii)&nbsp;the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if the Company terminates your employment without Cause or you terminate your employment for Good Reason and, in either
case, the Date of Termination occurs during the Post-Change in Control Period, a lump sum cash payment equal to your target annual performance bonus for the year during which the Date of Termination occurs; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) if the Company terminates your employment without Cause and the Date of Termination occurs outside of the Post-Change in
Control Period, twelve (12)&nbsp;months of accelerated vesting from the Date of Termination with respect to any of your then outstanding stock options, restricted stock units or other equity incentive awards (in each case, only to the extent subject
to time-based vesting); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) if the Company terminates your employment without Cause or you terminate your employment
for Good Reason and, in either case, the Date of Termination occurs during the Post-Change in Control Period, then outstanding stock options, restricted stock units or other equity incentive awards (whether or not subject to time based vesting)
shall immediately vest in full effective upon the Date of Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Agreement, you
shall not be entitled to any Termination Benefits unless you first (i)&nbsp;enter into, do not revoke, and comply with the terms </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr. John Thero </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 10, 2014 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a separation agreement in a form acceptable to the Company which shall include a release of claims against the Company and related persons and entities (the &#147;<B>Release</B>&#148;),
provided that the Release shall not require you to release (a)&nbsp;claims to enforce your right to receive Termination Benefits; (b)&nbsp;claims for vested benefits pursuant to ERISA; (c)&nbsp;claims with respect to your vested equity rights as of
the Date of Termination; (d)&nbsp;claims to enforce the Company&#146;s obligation to indemnify you to the extent such indemnification obligations exist; and (e)&nbsp;claims which legally may not be waived; (ii)&nbsp;resign from any and all
positions, including, without implication of limitation, as a director, trustee, and officer, that you then hold with the Company and any affiliate of the Company; and (iii)&nbsp;return all Company property and comply with any instructions related
to deleting and purging duplicates of such Company property, in each case within the time period designated by the Company but in no event later than 60 days of the Date of Termination. The Salary Continuation Payments shall commence within 60 days
after the Date of Termination and shall be made on the Company&#146;s regular payroll dates; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to
be paid in the second calendar year. In the event you miss a regular payroll period between the Date of Termination and first Salary Continuation Payment, the first Salary Continuation Payment shall include a &#147;catch up&#148; payment.
Notwithstanding the foregoing, if you breach any of the material provisions of this Agreement or the Nondisclosure Developments and Non-competition Agreement, in addition to all other rights and remedies, the Company shall have the right to
terminate or cease payment of the Termination Benefits. For the avoidance of doubt, you shall not be entitled to the Termination Benefits in the event your employment ends due to your death or disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B>Definitions:</B> For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Cause&#148; shall mean: (i)&nbsp;conduct by you constituting an act of material misconduct in connection with the performance of your duties, including,
without limitation, misappropriation of funds or property of the Company other than the occasional, customary and de&nbsp;minimis use of Company property for personal purposes; (ii)&nbsp;the commission by you of (A)&nbsp;any felony; or (B)&nbsp;a
misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;any conduct by you that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries and affiliates if you
were retained; (iv)&nbsp;continued non-performance or continued unsatisfactory performance by you of your responsibilities as reasonably determined by the Company&#146;s Board of Directors; (v)&nbsp;a breach by you of any of the material provisions
of any agreement between you and the Company including, without limitation, any agreement relating to non-disclosure, non-competition or assignment of inventions; (vi)&nbsp;a material violation by you of any of the Company&#146;s written policies or
procedures provided that, other than in the case of noncurable events, you are provided with written notice and fifteen (15)&nbsp;days to cure. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr. John Thero </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 10, 2014 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Change of Control&#148; shall have the meaning set forth in the 2011 Option Plan, as may be amended
from time to time, but only to the extent such event also constitutes a &#147;change in ownership&#148; of the Company or a &#147;change in the ownership of a substantial portion of the Company&#146;s assets&#148; for purposes of Section&nbsp;409A
of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Disability&#148; shall mean that, due to your illness or injury, you are unable to perform the essential functions of your position
with or without reasonable accommodation for a period of 180 days in any 12-month period (whether or not consecutive). Nothing in this Agreement shall be construed to waive your rights, if any, under existing law including, without limitation, the
Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 et seq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Good
Reason</B>&#148; shall mean that you have complied with &#147;Good Reason Process&#148; (hereinafter defined) following the occurrence of any of the following Good Reason conditions that occur without your consent: (i)&nbsp;a material diminution of
your base salary; (ii)&nbsp;a material diminution in your authority, duties or responsibilities; (iii)&nbsp;a material change in the principal location where you are required to provide services for the Company (subject to the relocation
requirements above and not including business travel and short-term assignments); and/or (iv)&nbsp;a material breach by the Company of this Agreement. For purposes of this Agreement, &#147;<B>Good Reason Process</B>&#148; shall mean that:
(x)&nbsp;you reasonably determine in good faith that a &#147;Good Reason&#148; condition has occurred; (y)&nbsp;you notify the Company in writing of the Good Reason condition within sixty (60)&nbsp;days of the first occurrence of such condition;
(z)&nbsp;you cooperate in good faith with the Company&#146;s efforts, for a period of thirty (30)&nbsp;days following such notice (the &#147;<B>Cure Period</B>&#148;), to remedy the condition; notwithstanding such efforts, the Good Reason condition
continues to exist; and you terminate your employment within thirty (30)&nbsp;days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B>Section&nbsp;280G Limitation:</B> Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of you, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section&nbsp;280G
of the Code and the applicable regulations thereunder (the &#147;Severance Payments&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, the following provisions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(a) If the Severance Payments, reduced by the sum of (1)&nbsp;the Excise Tax and (2)&nbsp;the total of the Federal, state, and local income and
employment taxes payable by you on the amount of the Severance Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, you shall be entitled to the full benefits payable under this Agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr. John Thero </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 10, 2014 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 6
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(b) If the Threshold Amount is less than (x)&nbsp;the Severance Payments, but greater than
(y)&nbsp;the Severance Payments reduced by the sum of (1)&nbsp;the Excise Tax and (2)&nbsp;the total of the Federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the Threshold Amount,
then the Severance Payments shall be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments shall not exceed the Threshold Amount. In such event, the Severance Payments shall be reduced in the following order:
(1)&nbsp;cash payments not subject to Section&nbsp;409A of the Code; (2)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and (4)&nbsp;non-cash forms of benefits. To the extent any payment
is to be made over time (<I>e.g.</I>, in installments, etc.), then the payments shall be reduced in reverse chronological order. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(c) For
the purposes of this Section, &#147;Threshold Amount&#148; shall mean three times your &#147;base amount&#148; within the meaning of Section&nbsp;280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and
&#147;Excise Tax&#148; shall mean the excise tax imposed by Section&nbsp;4999 of the Code, and any interest or penalties incurred by you with respect to such excise tax. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(d) The determination as to which of the alternative provisions of this Section&nbsp;9 shall apply to you shall be made by a nationally
recognized accounting firm selected by the Company (the &#147;Accounting Firm&#148;), which shall provide detailed supporting calculations both to the Company and you within 15&nbsp;business days of the Date of Termination, if applicable, or at such
earlier time as is reasonably requested by the Company or you. For purposes of determining which of the alternative provisions of this Section&nbsp;9 shall apply, you shall be deemed to pay federal income taxes at the highest marginal rate of
federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of your residence on
the date of termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. Any determination by the Accounting Firm shall be binding upon the Company and you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B>Taxes; Section&nbsp;409A:</B> All forms of compensation referred to in this letter agreement are subject to reduction to reflect
applicable withholdings and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes tax liabilities. Anything in this Agreement
to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section&nbsp;409A of the Code, the Company determines that you are a &#147;specified employee&#148; within the meaning of
Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred compensation subject to the 20&nbsp;percent
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr. John Thero </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 10, 2014 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 7
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional tax imposed pursuant to Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit
shall not be provided until the date that is the earlier of (A)&nbsp;six months and one day after your separation from service, or (B)&nbsp;your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment
shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original
schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you
during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which
the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such
right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any payment or benefit
described in this Agreement constitutes &#147;non-qualified deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the termination of this Agreement, then such payments or
benefits shall be payable only upon your &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation
Section&nbsp;1.409A-1(h). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties intend that this Agreement will be administered in accordance with Section&nbsp;409A of the Code. To the extent
that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&nbsp;409A of the Code. The parties agree that
this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided
hereunder without additional cost to either party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company makes no representation or warranty and shall have no liability to you or any other person
if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B>Other Terms:</B> Your employment with the Company shall be on an at-will basis. In other words, you or the Company may terminate
employment for any reason and at any time, with or without notice, subject to the Termination Benefits provisions herein. Similarly, the terms of employment outlined in this letter are subject to change at any time. You also will be required to sign
and comply with the Company&#146;s Nondisclosure Developments and Non-competition </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr. John Thero </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 10, 2014 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 8
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement as a condition of your continued employment and of your receipt of any post-employment severance pay or benefits, the terms of which shall be incorporated by reference into this
Agreement. A copy of the Nondisclosure Developments and Non-competition Agreement is attached. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <B>Interpretation, Amendment and
Enforcement:</B> This Agreement, along with the Company&#146;s Nondisclosure Developments and Non-competition Agreement and the Preserved Agreements, constitutes the complete agreement between you and the Company, contains all of the terms of your
employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company, including the Prior Agreements. This Agreement may be amended or modified only by a
written instrument signed by you and by a representative of the Company authorized by the Board. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of,
related to, or in any way connected with, this Agreement, your employment with the Company or any other relationship between you and the Company (the &#147;Disputes&#148;) will be governed by the laws of the State of Connecticut, excluding laws
relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of Connecticut in connection with any Dispute or any claim related to any Dispute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <B>Notices</B><B>:</B> Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in
writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to you at the last address you have filed in writing with the Company or, in
the case of the Company, at its main offices, attention of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <B>Assignment:</B> Neither you nor the Company may make any
assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent
to one of its Affiliates or to any person with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the
benefit of and be binding upon you and the Company, and each of our respective successors, executors, administrators, heirs and permitted assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <B>Survival</B><B>:</B> The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your
employment to the extent necessary to effectuate the terms contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <B>Enforceability</B><B>:</B> If any portion or
provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this
Agreement, or the application of such portion or provision in circumstances other than those as </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr. John Thero </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 10, 2014 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 9
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted
by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <B>Waiver</B><B>:</B> No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving
party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed
a waiver of any subsequent breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions about this Agreement, please let me know. Otherwise, please confirm your
acceptance of this Agreement by signing below and returning a copy to me. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signed for and on behalf of: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMARIN CORPORATION PLC</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signed:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph T. Kennedy</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Joseph T. Kennedy</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">General Counsel and Secretary</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Dated:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">January 10, 2014</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr. John Thero </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 10, 2014 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 10
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>UNDERSTOOD, AGREED AND ACCEPTED:</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Signed:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John F. Thero</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">John F. Thero</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Dated:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">January 10, 2014</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosures </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g659029ex10_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g659029ex10_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1P%9`P$1``(1`0,1`?_$`-@```(#`0`#`0$`````
M```````*"`D+!P$%!@0#`0`"`P$!`0$!````````````"`4&!PD$`P(!$```
M!@(!`@$%"@<+"@<````!`@,$!08'"``1"1(A,1,4"D$B%=9WE[<X6!DR(]46
M%W@Y47&Q<C.S)C:6&%J!0G,D-"4UM799H<%2MC<H&A$``0($`P,%"`P+"`(#
M`0```0(#`!$$!2$2!C%!!U%A(C(3<4+2LQ1T%3:!4G(C<Y.45196%PB1L6*"
MDK(STR0T-:'10V-4M'4WHB53@U<F_]H`#`,!``(1`Q$`/P!_CA!!P@@X00<(
M(.$$59=TGNA8I[<F('+YRYBK?L)=(MXEAW$0.O$ZD'@^D:A=+BDV4*ZA\>P+
MH/$NL(IJR"Q/5&HBH*BB%_T#H*X:UN00D*;L[2AVSTL`-N1$\"XH;!B$CI*P
MD#G?$/B%;="VLN+*7+RZD]BSO)V9U@8AL'N%1&5/?*3_`![0G<+^\0U7:WZU
ME@X[-^/)Q:C9I@8!NHPBR3@)C(5^TP\8NZ>N&4#;X%0BJ1#*J`F\0=HE,((]
M1_O$?1GT+OYHZ?.JUO(SLJ5B<NQ2"9`%2%?^)23MC^<,M<)USIX5SP2FZ,K*
M'DIP$]J%`>U6GV,Z5@8"+4^9_&BP<((.$$'""#A!!P@@X00<((.$$'""#A!!
MP@@X00<((.$$'""#A!!P@@X00<((.$$'""#A!!P@@X00<((.$$'""#A!!P@@
MX00<((.$$'""#A!!P@@X00<((.$$'""#A!'&]AWV5HO!66Y3!CVG1V7XO']G
MDL>/<@-UW5-;V=A%.'<>>?20?QHE9"=$0](=8J"2@E.J!TBG(:3LR+>Y=J9N
M[!TVU3R0X&S)>4D`Y<#CS2F1@)&1B*OB[BW9ZERT%I-S2RLMESJ9@)C-B,.<
MF0.)!$Q&45EW+V3\\Y%M&6,R72;R!D:WOSOK%9Y]X5X\=+`(E2:-2H>%A'Q$
M>F`)-&C0B3-L@4I$2%(`!SH3;+;06BA;M]L:0S1-IDE*1(=T[R3M),R3B23'
M-B\7:Y7JX.7"ZO+?K'%$J4HSGW-P`V`````````"RWLJ;TCH]NG4I&TRRC'"
MF:P98GR^DJL)(Z+:R[]/\S;ZX(;Q)$/2+,L0ZZW3QDB7;XI?*?E&XI:3^E6F
M'$4Z9W2EFZSRD@=-L>[3@!O6$$[(T#A%K'Z(ZK;-2J5JJY-/<@!/1</P:I$G
M<@K`Q5&E64Q3%`Q1`Q3`!BF*("4Q1#J`@(>00$.(YLA_-N(CSP@@X00<((.$
M$'""#A!!P@@X00<((.$$'""#A!!P@@X00<((.$$'""#A!!P@@X00<((.$$'"
M"#A!!P@@X00<((.$$'""#A!!P@@X00<((.$$'""#A!!P@@X00<((.$$4.>T!
M[F2.N>GY<'8Y=KJYOV[DG&)*M&1)SJ3[6ANTT&^1)>/;MS@Y]:E6LDU@&O0O
M4SB9\1.IDAZ:UP?TRB]:D]+5H`M5M2'E$]4N#]F"3A($%P\R)';&.\:-4+LF
MF?0]$3Z5N9+*0,5!K#M5`#$S!#>&/3)&*842[F/;`R!VZD=<9">=/IV!S)B6
M"D+)+'12%E5<Y1;%%QDG':+ALF5(T?&E?-UXQ10?2.D/3>?T)Q!C]"Z]H]:&
MM;9`0[35"@D;UL$^].2.\R(4!@#+E$*]Q"X=5NAT4+SQ4MJJIDJ63B$/@#M6
MY@2DDD92<5`GVIBJT0`P"4P=0,`@(?N@(=!#_*'-"C,P2#,;1&BYV$M[!W`T
MVBJ+<YA20S7K06(QG>%'K@%I*QU(&:H8UNZHF,*ZYI*!8'CG:I_$=20C%U#C
M^-+U2GB[I+Z-ZF55TR96NNS.HD,$KG[ZCDP4<P`P"5@#9#X\&=8C5.E4TE2J
M=UH`EI<S,J1(]DO:3BD%!)Q*D%1ZPB\;F51KT'""/@\E92QMAJGR.0<M7RI8
MUHL.JP0E;?>)^-K-;CEI1\WC(U)[,2[EHP;*/Y%TD@D!S@*BJA2EZB(!SV4-
MOKKG4IH[<RX_5J!DAM)4HR$S)(!)D`2>:/%<+C06JE577-YJGHTD`K<4$)$R
M`)J40!,D`<I,HC#]Y3V]_MLZN?/ACS\O\GOH-K/YJN'Q#G@Q7?M`T-\[V[Y0
MUX4'WE/;W^VSJY\^&//R_P`/H-K/YJN'Q#G@P?:!H;YWMWRAKPHE30,AT/*U
M0A<@8RN59R!1K(@LZK]OITW'V*MS3=NZ78N%HR9BG#I@\(@]:JHG%,YO`JF8
MH]#%$`KU915=OJ5T=>TXS5H,E(6DI4F8F)I,B,"#W#%EHJZCN5*BMM[K;]&X
M)I6A04E4B09*!(,B"#SB4?8\\T>J#A!'REXO=*QE4IV^Y%ME=HM)K#(9*QVV
MV3#"`KL&P*HFB+R5F)-=LP8MQ66(0#*'*`G.4H>40#GHI:2JKJA%)1-K=JG#
M)*$`J4H\@`F3'FJZRDM],NLKG$,TC8FI:U!*4C9,J,@,<(BA]Y3V]_MLZN?/
MACS\O\L7T&UG\U7#XASP8K/V@:&^=[=\H:\*#[RGM[_;9U<^?#'GY?X?0;6?
MS5</B'/!@^T#0WSO;OE#7A1*NA9`HV4ZA!Y`QK;JY?:-9FJCVNV^HS#"?KDX
MS2<KLU'45,1B[EB^03=ME$A,F<P`<AB^<!Y7JNCJZ"I71US:V:ILR4A8*5),
MIR(,B,"#C%FHZVDN-,BMH'4/4C@FE:%!25`$C`B8.(([HCZ_GFCTQX$P%`3&
M$"E*`B8PB````'41$1\@``<.:".188SYAG8FMS-OP?D>KY.K%>N%CH,S-U1^
M$@P86^INP9ST*JL!"`99HH<AR*$\2+ANJFNB=1%1-0TC<[1<[,^FFNK#C#ZV
MTN)2L2)0KJG\8(V@@@@$$1&VN\6N],JJ;4^V^PAQ3:E(,P%IE,?@((.PI(4"
M008Z]R.B2@X01S'+&:L0X'K*%TS7DVBXGJ+F6:0#>S9"M$/4H)>;?H.W+*)2
ME)MVS9GD7;=@N=-$#^,Y$3B`="CT]UNM=RN]0:6UL/5%2$E65M"EJR@@$R2"
M9`D8\XB/N=VM=FIQ5W:H9IJ4J"0MU:4)S$$@340)D`F7(#R1'/[RGM[_`&V=
M7/GPQY^7^3GT&UG\U7#XASP8@/M`T-\[V[Y0UX4'WE/;W^VSJY\^&//R_P`/
MH-K/YJN'Q#G@P?:!H;YWMWRAKPH/O*>WN/FW9U<_<_\`G#'GY?X?0;67S5</
MB'/!@^T#0WSO;OE#7A1U2B[<:JY.<),\<[*8&O+U<Y4T6%4RW0IV044./0A"
M,(V><.S&./F#P=1]SD=5Z<U!0#-6T-8TD;ULN)'X2D")*CU/INXJR4%PHGEG
M<A]M1_`%$Q(4!`0`0$!`0Z@(>4!`?,(#^YR&B=CSP@B/.7-M]7,!6%A4\W["
MX;Q)9Y6'2L,97\BY$JU0F'\$L\>1R,PSCYR39.G$:J_CUT2K%**8JHG+UZE$
M`FK;IR_WADU%JHJJI82K*5-MK6`J0,B4@B<B#+D(B"NFI].V1Y-->*ZDI:A2
M<P2ZZA"BDD@*`4093!$^4'DCE?WE/;W^VSJY\^&//R_R0^@VL_FJX?$.>#$;
M]H&AOG>W?*&O"@^\I[>_VV=7/GPQY^7^'T&UG\U7#XASP8/M`T-\[V[Y0UX4
M'WE/;W^VSJY\^&//R_P^@VL_FJX?$.>#!]H&AOG>W?*&O"@^\I[>_P!MG5SY
M\,>?E_A]!M9_-5P^(<\&#[0-#?.]N^4->%'@>Y5V]@`1'=G5P``!$1_3ACSR
M`'E$?^/\/H-K/YJN'Q#G@P?3_0YV7>W?*&O"B8T'.PMGA8FR5N7C+!7IZ.9S
M$'.PKYM)Q$Q$R+=-W'R<7),E5F;]@^:JE4262.9-0A@,41`0'E9=:=IW5,/I
M4AY"BE25`@I(,B"#B"#@0=D6MEYFH:344ZDK86D*2I)!2I)$P01@01B",#'M
M>?./I'-<K9EQ+@JK%N^:,E4?%5./*,H0MHR!9HBIP)IB1(X481996:=LV0OW
MA&JHI)>/QG!,P@`]!Y[K?;+C=JCR2UL.U%3E*LC:2M4A*9DD$R$Q,\\1]RNM
MLL]/Y7=:AFFI<P3G<6$)F9D":B!,@$RYC$;_`+RGM[_;9U<^?#'GY?Y.?0;6
M?S5</B'/!B`^T#0WSO;OE#7A1[.%[A^AUDF8BN5_<;6J:G[!*1\'!PT7F:A/
MI.7F99VBPBXN.9-YQ1P\?R#YP1%%),ICJ*'`I0$1`.?-W1>KF&E/O6RN0RA)
M4I19<`"0)DDE,@`,28^K.NM&5+R:>GNMO6^M02E*7VR5*)D``%3))P`B8_*S
M%J@X00<((.$$?S55202477431013.JLLJ<J:22291.HHHH<0(FFF0!$1$0``
M#J//Z`29#$F/X2`)G`"%#]7P5[OO>OR#M-+(JR^K.BX,8C$Y%BG7@YN<KTQ*
M-<:+)`H4[8ZUDM:4K<5>GOBHLV2)_>B3JQM^EPXX7LV!OHW^ZS+OMDI4`7>?
MHHR,\Y*B-\+/IZ?$WBL]J%T9M.VF09WI44*/8\HZ:\[\Q(B616Z+]>YOI9#;
MXZ?9,P>JDU2O"30+MB":<`0OP%E.K-W3FLJ&<'_V>/G2K+1+XWN,9!80]\!1
M#(="ZH=TEJ1BZ@GR6>1Y([YI1&;#>4X+3^4D1LO$#2C6L=+U%H('E<L[)/>N
MI!RX[@H$H4=R5$C$",O";A)FM34Q6[%&/(2PUZ5D8*>A9%$[:0B)J'>+1\K%
MOFZ@`=!Y'OFZB2I!#J4Y!#C[,O-5#27V%!;*TA25#$%)$P0=X(Q$<Z:AAVE?
M73/I*7FU%*@1(@@R((W$'`C<<(L7[3F[[O0W<W'N4Y1\[3Q3;3AC3-L<BH?T
M"^/K.[;)FL)VX&`BSNB3:3682\GC,DU61*(`N;K2N(FE$ZNTR]0-@>D&_?6#
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M9<Q`(YX3$]HC[=&K.J=6UZR]K9C.(Q&\OMYL6.[G6*XZD$ZG+^C@0GX*;;0[
M]T\;0LDR4:.$%C-?0HKI*D$Y/$F!A9S@OK2_Z@J*RVWM]52AII+B%*`SCI95
M))`&8&8(G,B1D<853CIH;3]@I:.ZV-D4SCKBFUI23D5(!25243E(Z0,I`S$Q
MA"PUQI]BH%LLE&N,.Z@;74)N2KMCA7R7HW<9,1+I1F^9KE\WB272'H8.I3EZ
M&*(@(#S>::IIZRG15TJ@NG<2%)4-A!$P?P0N572U-!4N4=6E2*EM92I)V@I,
MB/8(ANKV7_=,"&R=HE<Y,>@_"69\)"[<>3PB+)IDZFL2'ZCU*<S:;;HD$``#
M2"@AYQXN/'G2_P"PU92IY&7Y>R6EG^U!/N!#0_=YU;F34:0JU8XO,3/<#B!W
M1)8',XHPXKQ:H:6#A!"I7M)&SEJM$7CSM[8;2<35FM<#-[$9T;1:Y?'&XPQ?
M$SEIAHR7,50$V\<<:Q(3SPJWA$J4.U$.H+E`6#X(V&G8<>UE<Y)8;6FG8)WN
MNE*%$<_32V)>W5R0N''G4%4^PSHNU374.(54U`&YII*EI!W2DA;JMA&1!&V$
MD0`H@`@`=!#J'D#W>-/"@$J!E,PUA[.AH!J=M3CW8G*6Q>(:]E^;I]_K%&J4
M9</77E=@HU:L!/R3U&$0=MV#V3DG3XA#*N2+"DD@4$_!XSB9>^-6L-06"MHK
M?9:A=,TXRI:RB04HYLH&:1(`D<!*<\9R$,SP(T9IV_V^LN=ZITU+Z'4H2%E6
M5(D23E!`).&V<I82F8<YQIC+'^&Z+7,98KJ$%0L?U%FI'UFH5EBE&P4&R6=N
M'ZK:.8H@";=)1X[55,`><ZAA\X\62NKJRY5:ZZO<6]6.&:EJ,U*,@,3W`!#5
M4-#1VRD10T#:6J1L$)0D2`F23(<Y))YS'W7/)'KA.CO\]VC8"B7B\Z#XIJ-C
MPG"N(*//D/*K]\Q+;,GTVT,3'188Z5A7KPE:H\RD"S9Z].L66=BDJU%-F0%B
MK,KP?X=6>LI6M77!Q%4Z%GLV@#D:6D[7,P&98P($L@P5-1D0K?&KB9>K?4NZ
M.MS2Z5M2!VCI(S.H4-C<B<K:A@3/,K%)R@*2JM[V?_?L-1]L&V&[Y,G98-V<
M>0U,E/6G!4XFH93!8K+'MQ,"RB;=FVDEW`PL@I[T/0NT%5!$K4.EXXPZ/^D6
MGC<Z-$[K0!2Q(8K:VN(Y20!G2.5)`ZT4'@EK<Z<U'Z*KED6JO(09G!#L_>U\
M@Q)2H\BLRC)`C0XXF4/%!P@CCN<-?<)[*TU''F>\8U#+%(;S3*QH5FZ124O%
M(3T<V>M&,NBW6Z`D_:-9)PF10H@8I%CA[H\DK5>+I9*DUEI?<IZHI*2I!D<I
M()'<)`/L"(RZV:UWRF%'=V&ZBF"PH)6)@*`("ASR41W"1"&GM".F>O6GVSF(
MF6NE"98TK&4,2.[1/TZ'<OEJZTL4):WL&:1A&D@Y=GB4Y*/]""S=(X-_2I>,
MA"B<_5N.#6IKSJ2Q5*KTZ7WZ>HRI6H#,4E(5)1`$Y&<B<9&1.`A-..>EK+IF
M^TQLC78,U%/F4@$E.8*4F:9DD3`&`PF)@8F*)*TV;NK+6VKE%-=NYL,&V<(J
M%`R:S=>4:)+(J%_SDU4CB4P>Z`\UM\E+"U)P4$&7X(Q>C`75(2K%)4,(TW9C
ML^]L>SQGJ<CI7A!LFX;`0RL#7W59?)@HF'4R$G79"+D4%"B/D.54#@/N\1)O
MB1KIAS,BYU1(/?*"A^!0(_LCH8YPTT(^UD7;*8)([T*0?PH4#_;"U?>![!U(
MUDQ99-KM/'UA''M%!.4RCB"SR2MAD*G75G:+4]QH%F<E&;>Q$(LX(:082"CE
MR@U\;E-R)$CI!N/#;B[4WVX(T_J5*/+'<&GDC*%*E/(XD=$%0ZJD@`F22F9G
M&!<4>#=/8;8YJ'2RW!1-2+S"E%65)(&="CB4I/6"YJ`)5F(!`J-TM[M>ZND=
MAB%*+E2=R!C%JX0+,84RC,RELH<E%E4(+AI!C(N74K1'YTB]$G42JW`I^@JI
M+I@*1M&U1PYTOJEE0JJ=#->1@^T`AP'E5(2<'*%@\Q!QC+-)<4=6:2?3Y/4+
M>MX(S,.DK;(WA()Z!EL*"G';,8'1!TGW"Q?O3KM2MB,4B[:0]D*ZC+#6)0Z)
MYRC76&,FA9:=-F0Z(JNXIRH4Z2Y`*F\9K(.2`4BQ0!,=4:;K])WIVRW"1<;D
M4J'5<0KJK3S'>-R@4G$0\VD]3V_5]D:O=MF&G)A23UFUCK(/<F"#AF24JD)Q
M_/8+1'3[:N=8VC8C7O'&6;/&5XM4C;':8@ZL_'5U-Z_DDHAA,LW#219M$9"4
M<K$!-0HD56.8H@(]>%GU9J33[)I[-6/4["EYRE)Z)5("92003(`;-@$?V\Z2
MTWJ!X5%YHV:BH",@4H',$@DA(4""`"I1&.!)E&:#O?AVG:_[G[/X4Q^W<M:+
MC3,]UJ]/9OG2L@[85QI)&6B(U=^Y$SEZ>-9N"H`LJ)E%`3`QQ$PB(O/I&Y5-
MYTQ072LD:M^F0I9`D"HC$R&`F<9#`;HY^ZWM5-8]5U]JH<PHV:EQ*`220D+(
M2)G$R$A,XG:8DEV;=:<3;9=P;#N',W0!K3C5W%9!MD_5P?/8UO8E*;396:B8
MF1=QJ[5^6*5ED43N4TE4S+I)BD)@*<W(/B;?+AIW1U3<K4H-UP4VA*I`Y<ZT
MI)`((G(F4P9''=$_PGL%NU+K6FMUV27*&2U*1,IS9&UK`)2099DB<B)B8WP^
M./:)[98LP8CI-@/T`!T`P4U`'/X/@ZB^!;UT1Z>Z*G7KY?/Y>*/]HNN,V;TI
M5S]WA^#9#H?9QH64O1=+W<IG^&<_[840[Y';?Q)KGN#KKCG3Z@GKG]YNMF:1
M>+&DPY=1"61T+@TJT>A6'5A>KJQ+2SFFFB?JRKD6Z+E,QB"F13P%8_A1K:X7
MK3=;6ZD="_(5S+I2`>SR9SF"1B4R49@3(VS(G"P<8M!VZRZEHJ33+2D*KT@!
MH*)':E90,I69C--(D52!GL&`7\L%=FZE/3=5M,+)5VS5N5?P5AK\TQ7C9B$F
MHMRHSDHJ4CW::3ED_8ND3)JI*%*8ABB`AS8F'F:EE-13J2MA:0I*DD$*!$P0
M1@01B#&&5-/4T;ZZ:J2INH0HI4E0(((,B"#B"#@0<0<##$G9([S3W4*<B-7]
MEY]Y(ZN664*VIMP?JK/'.O\`/R;D1.J<QQ475Q3+NUA.^;%ZC$+F%V@7T1G*
M9\7XI\,4:B:5?K$@)OK:9K0,!4)`_!VH'5/?CHGO2-YX1<6%Z=>3I[4*RJQ.
M*DA9Q+"B?%DF:AWIZ8QS!3[D?(,)9@RE(MZTDHR2:-I".D8]RB\82#!XB1PS
M>LGC<ZC=TT=-U"J)J)F,0Y#`8HB`@/%$6A;:RVX"EQ)(((D01M!!Q!!VB'-0
MM#J`XV0IM0!!!F"#B"","",01MCE>;L`86V3I/Z.,\XUJF5J+\+L)\*O<HQ.
M5B23<61RG'2B;=02^C?,TWBI4U"B!B@H8`\_/?:[O<[)5>6VE]RGJLI3F09'
M*93'<,A^"(^ZV>V7NE\BNS"'Z7,%95B8S`$`]V1([A,)T^T`]I_6G4W$U$VF
MUDJ@8NC9'(\=C3(>-V$G)2%3<GL4%/S$#::TUF7<@[@7K5U6U6SMJBMZFLFY
M3.FDD9(XJLKP>XA7S4%Q>L%]<\H6E@NMN$`+&524J0HI`"@<P()$Q(@DS$E<
MXU\-;'8+<SJ#3[98SU`:<;S**#F2I25IS$E/4(*098@@"1G;IVK>S?IKC'6C
M77-&2<15[*NP5PJ6/LVOKY=3.Y@*G89QE&7:M1M*AS.$H6$;5$KAL5-<$#NU
MW2)EE%1`Q2$SGB!Q*U+7WVMME%4*I[.TXXP&T2&=*24**S+,<\CA.0!D!M)T
MWAOPQTQ;=/4-TK*=+]X>:;?*UDG(I0#B0A,PD9`0)R))!),I`,`\Q^-HBC+<
ME_/H;%7M)EWU*-IFV*A5A3USF:MKQ)2-#ZU6'$ZZ[R]VN,M*H6D_65+ZRB0"
ME>`"?5,"".KZ90R;*R5:3>N:IK_B4JJ`'.FK<V@IZ'4P/>XXSC(-4O.HOCR4
MZP8M0Z'\,I%.2WT$[W'$JZ77Q'?882B,'PK:?\3KC+^P^I7QZY/=G3_42H_3
MJ_W<5[RA[_\`0*7XND_?0?"MI_Q.N,O[#ZE?'KAV=/\`42H_3J_W<'E#W_Z!
M2_%TG[Z*^>Y3LMF+`FNSL,>]\8=Q9S*,DZQK)XHQO0<!M3%I<W!2@7&<L%IH
M,U8)FM1Z49X6B)DRHKKN7A"I*%\)S%N6A[';;O>AY9I3T:U3I#H==<J#TTJ&
M1*4.)2E1GB9S`"3,8@&DZ]U!<[38RFAU>FYO5*BT6FFZ<=!22%J4MM:E)$I)
MPD258'`D?=:'8,KVNVN]/C,?]^[!6L4GD./B,E9&Q16(G6RWI5N\V&`B2/H=
M_:+9>BSDK(0+!HW8K>,B**:S<X)I@`B)O)JVZO7F].+K-(5=>VP2TVZHU*,S
M:5&1"4-Y0%$E0VF1$S'KT;:Z>QV-I%'K2BH'7P'764BF7E<4D3!6IW,2D`).
M``(,AO-@6-H+*F0;[5*?2/:/:EDNTS4RV)%4&K8UU<EY^V>I>*3?0T;'0]R=
MRCA1S&LEO&*"9SII`8X![WE.KG;?1T;E35:)=8IT)Q<6Y5)2B>`)*D`#$C:8
MN]O1<*ZL;I:/73%14K5T6T-4JE+WR`2Z2<!/`&*:?:1M$OT&[&P^W-#AC-\9
M[+.E6M[!FB(,:]G.*9"M(K*^`/`W)D:OM?A(G7RJR#.0./X0!S3>"&K?2ME5
MIRK5.NH1-N>U3!.'Q:CEYDE`C)^/FC/1-Z3J>B1*@KC[Y+8E\#I=SM!TQABH
M.DPM2(`("`@`@(=!`?*`@/G`0]T!YN<+X"09C;&@5[.SO6.RFJ"FO-XES.\M
MZL(1=915?.A6D+-A^0%PGC^:`5CBLNI6"M5()R(`()IM&AS#XG`<3GC1I+T'
MJ'TS2IE;K@2K#8EX2[0?GS[0<I*@.K#P<#=8_2#37H:K5.Y6\!.)Q4R9]F?S
M)9#*<DA$S-4,,<QJ-O@X00K![5/]6_53Y?YGZ/Y;F_?=_P#ZY7^:)\8(7;[Q
MGJ_0>=J_4BM?VC33!3&64<1;D5*+(E3=@ZE6ZGD<[-N":,?F&IU=J#&4=^B2
M(BF>\4MD0P&$1.JZB'*AQ$RG4;SP4U.*Z@J=,U"OXFC<4MN>]E:S,#W"S[`6
MD#9&?<>=)&@KJ;55*F5-6-I0[+<\A`Q/NT`$<I0XH[8H2UNSQ<=8,]8FV!H*
MQR6C$]VAK:S:E6.BE,L6:_HIZM/3IB`C&VB`7=1[DOF%!R;FO7VT4U^L]19Z
ML>\5#2D$\A/54.=*I*'.!&*:<O=5IV]TUYHS)^G=2H;@0#BDG'HJ$TJEB4DC
M?&K+A7+E,SYB/&^:L>/PDJ3E&FP%VK;H1)Z8(Z?CT7R;1X1,QRH2,>=4S=RE
MU$4G"1R#Y2CSGS=+=4VBXOVNL&6JIW5(4.=)E,<H.T'>"#'26TW.EO-L8NM$
M9TM0TEQ/+)0G(\A&Q0W$$1[?)F1:GB''5ZRI?)-*%I>.:E8+M:I582@5C`UF
M+=2\HN4IS$!58K1H8$TP'Q**"!0\HASYT%%47*M9M](G-5/N)0@<JE$`?VG'
MDCZ7"NIK70/7*L5EI&&E.+/(E`*C[,A@-YPA1#4;'ENVAUU[OO=WS-$N6EFS
M[@O9C'.!XV2$SC\U\81./9EG-#$JKD'Q-&;2(C:VW<)"7J$2^#S+FZL;J&MI
M[#>]-\.;8H%BCJZ5Q\C#,Z7$E,^<DJ=(/MT<D+-IZAJK_8-4<2;HDBHK**K:
M8!QRMAI05E.\)`0RE6!Z"P=L*!D_`+_%+_`'&3A5E=8]V'>_94OJY;5_+K6?
MH[C.*I]X'^N4'FBO&&'"^[CZO5WG2?U3#5'%_AC(^6O%UJ^-J9;,A7>8:5ZG
M4>N3-LM,Z_/Z-G$5^OQ[B5EI%R;H(^B:,6ISB``)AZ=``1$`YZ*2EJ*ZJ;HZ
M5)74NK2A"1M*E$``=TF/-65=-04CM=6+"*5EM2UJ.Q*4@E1/<`C/KV$UYV,[
MH.)MV^\`J5^TJE/R2TB,7XV69BJ^D<#T%%:.LSR/.3^3#&=?<1J[@R9!2>O$
MYDXB"B12F<2RWNRZ"N-KX;B1J'6"77)X!]R12#\*H*`GBD%H;#,)3J#3]]XA
MVZ[<2U333M/@--$8EA`DL@SE)I/9YB,%$.JP(D:&P,8!*<ASD,42G(HF<Q%"
M&*(&(HFH00.0Y#``E,`@("'4.:\0")'9&()4I"@H8*!C25[)&_)=Y-/(!.X2
MP/,ZX)+%XQRX5PX!61GQ91Y0IV1E2C^,.2[P;41<J#^%+-'H!T*!>)!Q3T@=
M*:E7Y,F5IJYNLR&"9GIM_F*.`]H4;YP_G"36@UAI=ORA4[O2`-/3,RJ0Z#A]
MV!)1WK2N6$HN,YFD:E!P@A'?VJGZSFK7R#VCZ07'&K^[]_0Z_P`[3XL0H?WD
M/ZU;_-3XQ<+"U/\`K95/^IZ]_P`X9<WFI_EW/<*_$87:A_G&_="-?MM_LS?_
M`$"7\V7G-U76/=CJ&GJCN1$+N%6ZHT;17;NRWHS4*PUUWRRQ?)/!("+UU.TR
M6@(>,#Q^07$M-R;=LB`>^,LJ4"^^$.6/1E-4U>K+:Q23[<UK)$MP2L*4>X$@
MD\PBL:XJ::DT=='JN78>0O`@[RI!2E/=4I0`YR(RGTP$J:93?A%(4#?O@4`'
M_P`>=!HYM+(*R1L),/`^RJQEO0UMVCE9`CPE%D\XUQO516\8,EK'&4-D%T59
M`8/`8P,W<.FL8O7J9,"CY2CQ4_O`KIC?*!M$O*TTJBKERE?0G[(7*'#^[BW4
MIT]7.+GY(JJ2$\F<(.?_`,2WCR2Y(:CY@$,7&7'W7OVE6[?ZPEW_`)YOQ^.'
MGJ/:_,V_Q1SMXH>OMT\[<_7,2Y]G;_:I8=^3W-GT=RO*YQI]0*GX9GQJ8L_`
MC_L&G^#>\2Y&C'Q*H>N%0>^%^U5[0?R@5CZ><>\87A5Z@:C^!7_MW(7#B[_V
M#IKSAK_<(B1?>Q[,D=N%!RVS.ML(QB=I:S%"M9ZNS(W8,<_0,6V(5&/=*&,B
MV:Y*B&:'HXQ\?H5^D!63DW0&ZK>$X6\3EZ:>38[VLJL#BNBHXFG43M&\M$]9
M/>GI)[X&:XM\*6]5,*OUB0$ZA;3-21("H2!LY`Z`))/?CHJV)*4'9*-D8>1D
M8:8CWL3+Q+YY%RT3*-%V$E%R<>X4:/XV18.DTG+)\R=)'2614*4Z:A1*8`$!
M#C?-N-NMI=:(4TH`@@@@@B8((P((Q!&V$H=:=IW5,O)*74$@@B1!&!!!Q!!V
MC:##./8W[T2^O,C6]/MJ[.LO@:8?(1.(\G3;LRI\+RT@X\#>J65\Y4$2XKD7
M2H`W7,/2`7-[[_43B+3!^*_"\7A"]2Z?;`NR1-YI(_;`=^D#_%`VC_$'Y?68
MG@]Q8-F6WI?4;A-I49,NJ/[`GO5$_P"$3\6<>I/*]`BLBX12<-U4UVZZ9%D%
MT3E51615*!TE4E2"8BB:A#`)3`(@(#U#BH$%)*5"1$.$"%`*29I,+M>T]?LW
M(3]9;%__`+5R5S9N!/KLOS%W]=J,3X^>I37_`"#7BWHN9TX^J'JM^K?@[Z,:
MOS,]3>LEP\^?\:N-.TIZKVWS"G\2B)(<A(GXHQW*;V=38N^&C^Q/0]SF8H58
M$MCINT:YQTE?>E5AO&@NSOE2E;4D6JJ=8DGK*Y@,5D`I]$A('-8TRI@65D+U
M8];%=+^&2FH(;Z:M[:THZ?7P'?8XSC(=4-.KO;Q3I"GNB>C_`!*U4X4YT$[E
MM+5T>IB>\Y)1%_U2Z?X83%W]M=0_B#R>STOU\J?T*O\`>Q7_`"=_Z@4?Z=)^
MXCR#.Z"(!_\`F%Q;Y1Z>6[:A@'^41H0``<,]+]?*G]"K_>P>3O\`U`H_TZ3]
MQ%$5*2FM^>XF7,V`^V)6;#AC7`M6"ZZCX?E\1TZJN1A%YUJS"^7@\!`TBUFM
M-^1<+N"D8.1?1+$&I`.@0RW-9JE-Z0T7Z,N]^<1<ZW/DJWDO+6,V6?9HS*6C
M(W(#I#*LYL"91C=&VYK37'I.SZ>95::')GHV5-(0<LY=HL(2A>=R9/0.=L%&
M(&:+W1:701ZC[,+B[J/E'^FNH?Q!YDV>E^OE3^A5_O8V3R=_Z@4?Z=)^XB9.
MC-(9V3-1I*]]E'&&BJ]+K;ZT4S-K9WKY:);\ZP?1\*2MP@8\J<78H21?0DN\
M7]<*J"8(MU$C>50.5C5E6IBUY*35-1=@ZX$+8(J$C)(JS'M%J2H!24B4MI!W
M1:=(T+3MU[2JTI2VA3396A]/DZE9P4I"1D;0I)4E2CF!E))!VB)U;V:F5+=S
M5G+&NMK!NV4N4"=S3IY9/QGJ60X,WPI2+0B8"F5(6,GFZ0.2DZ&79*+HB/A5
M-RIZ2U%4:6O]/>J>9#2Y+3[=M6"T^RF<N10!W1;]8:;IM6:=J;'42!=1T%'O
M'$XH5RR"L%`;4E2=\98M^HEMQ=>;CC6_0KJN7>@6:;I]M@GA1(YB;#7I!>+E
M62GN'*D[;&\!PZE4(('*(E,`\?ZBK*>X4C5=2*"Z5YM*T*&PI4`0?P&.<5QH
M*FV5SMOK$%%4RXI"DG:%))!'L$2Y(ESVX=R9O1';S%N?F9WCBI,)`]4RO!-#
MG`;%BNT'096MIZ$O4KE[#E(C+,2B`AZ_'H^X(\KFM],M:MTY46A4A4$9VE'O
M74XH/,#BE7Y*C%IX?:K>T=J>GNZ9FFS9'4COFE8+'.1UDCVZ4SV1J1UZP0ML
M@(.TUJ39S5=LL1&S\!,QZI5V$M"S#-&0BY)DN7WJS1\Q<$53,'D,0P#Q!7F7
M:=Y=.^DI>0HI4D[0I)D0><$2,=%6'V:EA%33J"V'$A25#$*2H3!',09B/<<^
M<?6%8/:I_JWZJ?+_`#/T?RW-^^[_`/URO\T3XP0NWWC/5^@\[5^I%T^ZVI,)
MN[HG=M>Y))F2=LV-X>6QU+NRD\-=R?6XIM+T:9*L;H+9`)IN1L[,40$S!RNG
MYCCS,-+ZB=TMJUJ\H)[)M]0<`[YI1(6.<Y<1^4`=T:OJS336K-(/658';.,`
MM$]ZZE,T&>X$]%7Y"E#?&7;8(";JD].56S1CJ$LE8F92NV&&?)BD]B)V$?+Q
MDO&.TQ\I'+"0:J)'#_U$'C[L/-5+**AA04PXD*2H;"E0F".8@SCG354SM'4N
M4KZ2EYM92H'`@I,B"-Q!P(W&'.O9A]UQLU$R-HU=98ZDQCLS_*V&?77("9>B
MS<BW0O=48%54`WAK5KD$I))(@"(IRZX]`(B/18>/&ENPK&=5TJ9-/2:>D._2
M/>UGW2`4D_D)WF&Q^[UJ[RJA>TC5J]^8FZS,]X2.T0/<J(6-YSK.P1)'OXYJ
MN63CZY]K/!3Q0^7-R+Y6E[T+10XA`8GBY\I&AIDJ)@42B96P1ZLD[,/0H1M>
M=`?WBGE@^$5KI:$5NOKL/_76UI0;GWSI3CE_*"2$C\IQ,L1%CXQW:JKS0\/K
M0?\`V5S>07)=ZT%23FD00DK!6HC8EI4\#%CFRV%J7KGVG]@L%8[:"SIF*M)\
MM4R"(<I"N'3>'Q/8$'$J_$@`124FGOI7CM0/Y1RNH;W>4JQ72JO7$.BNU:9U
M51=65JY!-Y,@.9(DD<@`B[:BM5+8^&E?:*(2I:>T/H3RF3*IJ/Y2C-2CO))C
M+_)^`7^*7^`./I'.]76/=AWOV5+ZN6U?RZUGZ.XSBJ?>!_KE!YHKQAAPONX^
MKU=YTG]4PU1Q?X8R%O>_7G^\9%4P/VK=>7J;G-.XML@`OQ&RIA&MXI;S8`P2
MFCH]3LHNP346N_?''H)8>"=`<!37#KMG".STM$*O7]Y$K7;6U=G/OG2G'+RE
M*2$I&];B98B,+XQ7JKK54?#RR&=UN3B2Y(]5K-T0HC$!2@5*(G)#:IB2HO&P
M#KCC;7C7;'FL]1AF3K'5"H#2A*,9!DW51LS=1BHC9I2>9G!5L\>W&1=NWD@!
M@,19=VKU`0'IS*KQ>ZZ\WIZ^U*B*UYXN3!/1QZ`2=H"``E/(`(UJRV*@LEC8
ML%,D&A99[,@@=.8Z:E#82X2I2MQ*C&;?W3M))'0O<?(V'FS5P&-)U8V1,)R:
MH*F3>XQM#YZI%Q/K*I0]8?TN00<0SHWX1SLBJB`%5+U=[A_JI&KM,L7)1'ER
M!V;XY'4`3,MP6)+'(%2W&$)XEZ1<T=JE^WI!\@</:,G'%I9.43WE)!0K>5))
MV$1[GM.;TO\`07<*D9/DG;@,2W,4,;YPC"&4,BIC^>D&HC9B-R=06DJ%*$2E
M4.@>,Z2*Z`"`+FY\N(FDT:OTV[0H`](M>^,'_,2#T9\C@F@[L0KO1'UX8:R<
MT9JAFM<)]&O>]OIQ_9J(FJ7MD$!8PF<N42S&-.:-DH^9CH^8B'S23BI5DUDH
MR28.$G;&0CWR";ID^9.D#'0<M';94JB:A#"0Y#`("(#Q$EH6TLMN`I<22"")
M$$8$$;B#M$="&W&W6TNM*"FE`$$&8((F"#O!&(,?MY^(_<([^U4_6<U:^0>T
M?2"XXU?W?OZ'7^=I\6(4/[R']:M_FI\8N%?J\LHWL-?<(ME'BS>=AET6:(E*
ML\51DFJJ31$QO>E5<G*!"B/D`Q@Z\WM\!3*TDR!2<>3#;"YTBBFI0I(*B%##
MEA^G-'>\V(U^IK^X9-[1>VE)KL4W+ZQ9[58(MO3([H7P$4G+3!4^P,8EMX@#
MJHJ!2_O=0XGUKX6V:\U0IJ'45O<>4>JE,UGW*%.))]B'=O'%>\V.D-57:=KV
MV4CK*4H('NEA@I'L[85Z[BO>3V6[C#./QW8F=>PQ@EE+-94N+J@_E))&=DVB
MH'CI?(EJ<MT9"T_`R@^E;-D&31DDJ`*^KJ+D34+OFBN&5CT4HUK)7578I([5
M8`R@[0VD8(S;R5%1&&:1(A<-=\5[]KI":!T(I+0%`]D@DA1W%Q>U>7=()3OR
M9@#$GNV_V'F^\$#'98E]P\-+8D9R*#2U0.#E9RY93C7GHR.3UJPM+A`5%GCR
M8<M^O@5=M)'WGXU)%8G01@=;\7%:5>5;FK;4BXE,T*?RH:(V9DE"EEQ(W@%/
M(2#%CT%P8;U8RFY/W.E-N"AG2P5+=$Q/*I*TH#:CN)S"6(2H0\]KSKWB;5G$
M%,P9A*JMJACNC1XLHB-1.=R\=N7"IW<I.3<DMU=3%@G)%91R]=K"*BRZAA\A
M?"4%0O-YN-_N3MVNCA<K753)W`;`E(V!*1()`V`0X5DLEMT];&K1:6PU1,ID
M!M).TJ4=ZE'$G>>:0CM/(N)6,N/NO?M*MV_UA+O_`#S?C\<//4>U^9M_BCG;
MQ0]?;IYVY^N8ES[.W^U2P[\GN;/H[E>5SC3Z@5/PS/C4Q9^!'_8-/\&]XER-
M&/B50]<*@]\+]JKV@_E`K'T\X]XPO"KU`U'\"O\`V[D+AQ=_[!TUYPU_N$0U
M]Q>H8^%G.][V6FNS\98-L]6*XW9[(0D>9_D?'D4@DW;YYAXYN4!D(M$IDD$,
ML13)'HB;H`3B!`;J#ZR5`Y]SX5\4%6%Q&GK^LFR+5)MPG]@3N/\`E$[?:'$=
M&<L!XN<)F]1M+U'IYL)OR!-QL"0?`&T#_P"4`?\`V##K2S(CNVCEDY=L'[5P
MS>LG#AB_8O6ZK9VS>-53MW;-XT<$(NV=-ETS)JIJ%*<ARB4P`("'&V2I*TA:
M""@B8(Q!!V$'D,)BXVXPX6W`4NI,B#@01#8G8L[TYL?+U'2;;JUB-"=K,Z[@
M3,=B?&,-)=KJ)-(G%UZDG(B!*>X4,"4+)K'Z1:@E:+F]4,B=JN_%GA?Y6'-4
MZ<;_`(L`JJ&4CKC:74`=_O6D=?K#I3S,WP<XLBF[/2>I7/X7!-.\H]3<&ED]
MY[51ZFP^]R[.RWVGH0'MN08@/4!V6Q>("'F$/S4R5Y0Y1>!/KLOS%W]=J-$X
M]^I37_(->+>BYK3CZH>JWZM^#OHQJ_,SU-ZR7#SY_P`:N-.TIZKVWS"G\2B)
M(<A(GX7RWDMV`8S9[(K&[=\3+^GEF00J'PCKO5;A2XJ#H8*4V"5:*LV,K7'\
M@@:T,SIRRGI%3^)1Z8P="B`!L&EF+LNQ,*IM+4UQ8.>50M"BISIJG,A0'1,T
M"6Y,8[JAVU"^U`J-3U=`\"B=.A1"6O>T$``#O@0X9XS7.<I`1+_/W5;_`!+V
MP'S@X[^*'+!Y-?OJ31?%K\*(#M;)]<J_]-7]T0QWVV4H^(]=I^7UW[Y&T&U>
M3;-*1]+88OB;I45X?X"FTG0VJ<M[N%K<?(L(%G`-UT""@N1=1\Y;D+[P5#$M
M6C[)57.](;O&EJ"@H&TE9=*%3S)ED2@%1!45$'$2R@[Y13M<WVEM%A6NT:HN
M%;<75!M+6=0&54\ZE'`A.4$"6.92=TR/1]O*CZ=X:UUJLNMWO[!J?E#*4?'W
M++&+</6JDQ\3"3)BN4Z_"3+J7KLC*/YZ`KRZ2+T#J^A1?'7(D'A#QG^FM*W4
M5SO;C8TNW<*"G)0TZ\E1*AAF4`%`!*E`E.$RF1/(/QH.UV"U6%MU>I7J&X5*
M0XZVR2D))GE2HRQ4E)Z6X**@,,3.K\_=5O\`$O;`?.#COXH<J/DU^^I-%\6O
MPHNG:V3ZY5_Z:O[HO"[=M2CXS#DC>ZUO#D[?"BY,G5)>G91R-*0,PC%-8`SF
MLRT)5WD#&QB)HX)N-7%<%"B8')#``]`YEVLJA;ER32OVMBTU;")+:;!3/-)2
M5*!)QRD2YC&I:,IVV[:JJ8NC]UI7EG*XX<V7(2A24[\%`A0PD1LG.<_^5"+?
M"2GM,NAX4;(]2WKQ[""G6,IK1^/\XD8H@#>+R-&L`1I-P<IIE`$4KE76!HYP
MIT`@/8U$3"*KL/$TO`O5WE5$YI.M7[_3@N,3VELGIH'N%',!MDL[DPI'W@=%
M^35C>L*!'O+\D/R&QQ(Z"S[M`D3@`43ZRX5)XPT+-#VWLU^]/Z9-?9W3N]2Q
M5LA:X-DY+'QW;CQ/;#A2;D%"M6J13AZ18^.K`Y^#SCXA!-@\8$```H\4GCAI
M/T9>4:DI$RHZTR<D,$O)&W_[$C-SJ2L[X<_@)K+TO8UZ9K%3KJ$3;F<5,J.P
M?!J,N0)6A(V&&:^85#`PK![5/]6_53Y?YGZ/Y;F_?=__`*Y7^:)\8(7;[QGJ
M_0>=J_4AGFE_U.J?_3,#_P`K:\PBJ_F7/A%?C,,%2_RK?P:?Q"$,?:/M*OT!
M[:QVR5/ASM<;[2MW4M.*MTA!A$YI@$DDK@V.("8J![?$&:RY/%X16="^,`="
M#T;G@EJCTOIU5CJ53KJ`@)GM+*NI^@9HY@$<L)EQ[TCZ'U&F_P!*F5#7@J5+
M8EX?M!S9YA?*5*7N$4TZ<[*6G4'9S#6Q=2.X.\QI<H^3FHMNL9#\Y:8]$T5>
M*HL8#%**5BJKUVU+XO>D5.13SD`0TW4UBI]2V&ILM1+*^T0DGO5C%"_S5@'G
ME+?&3:2U#4:6U#2WRGG-AT%0'?(V+1^<@J3S3GMAQ'LW5:P[S;F[7]W;)\9(
MMX>7LDSA35V#FR$.I6Z:Q0:LY%VT,0XHINH*GILHA11`!16?OY8>OB$>+3Q+
M?9TIIFW\.:!22ZE"7JI2>^622`=\E+S+D<0E+<-;PN8>UAJBX\2Z]*@RIQ3-
M*E7>ID`2-TTM9433@HK<WSB['N(_4(W1_5;SO]&EDYEVB_6^U_\`(4_C4QJN
MN_4J[_\`&U/BEQE2$_`+_%+_``!SH+'-Q76/=AWOV5+ZN6U?RZUGZ.XSBJ?>
M!_KE!YHKQAAPONX^KU=YTG]4PS;E#)5,PUCB\Y8R),MZ]1<=5:;N-KF7)B@F
MP@X!@O(OU2E,8HKN#(H"5%(OOUE3%(4!,8`'"J"AJ;G6M6^B25U;[B4('*I1
MD/8Y3N&,,!<:^EM5"]<JY012,-J6M7(E(F>Z>0;29`8PF5VSM^=.K'N[M-W)
M]\,^5'&^6[K+.:3@#'$Y#W6>?4#'CEH@T4D&Z]?K4TP9#'TULPK[4WI065Z2
M:IR!ZP!CLUKK2.I&-+4&B-)TCCUN:2%U#B5-I#C@,Y$*4DF:RIQ0E(>]@'HX
M*WP_U?IJJU9<->:MJDLW!U913ME#J^S01(D%"%)Z+82TD@@D=H2,9E@[[\OM
M1_;(H_\`9'*GQ"YC?V5<0/FUW]-G]Y&V_:OP_P#G%/Q3_P"ZBDSOD[9]K[?/
M62-E<2;2T";V.PA,'L>-6*=7R&P?7*O3(MF-VQZ$E)4MBR1-)M4D)!F*ZQ$B
MOHXA.I`6.;FI<*=/Z[TC?BW<:!U-EJDY73G;(0I,RAR0<)PQ29">54\9",DX
MP7W0>LM/!RWUR%7ND5F:]Z>!6E4@MO,6@!.06)D8IE,9B83R\@A^Z`A_D$!_
M\AXS$*=B.[#Y_LXF_@9ZUZ?ZC9$FR.,K:UQS4*,=ZX,:1M>"W"Q&<&)/2B)G
M3G&\FJ6(6$!]Y'K1WD$?&;BB<;-'^A[R-1T2)6^N4<\MB']JNX'1TQRJ"^:'
M4X$ZV%[L9TW7+!N5"GWN>U;$Y#XHD)PP""V,2##*?,/C>X1W]JI^LYJU\@]H
M^D%QQJ_N_?T.O\[3XL0H?WD/ZU;_`#4^,7"PM3_K95/^IZ]_SAES>:G^7<]P
MK\1A=J'^<;]T(U[G49'34*XAYA@SE8F6BU8R4BY%LB]CY*.?M#-7S!\S<$4;
MNV;QLJ9-5)0IB*$,)3`("(<YOA:VG0ZV2EQ*I@@R((,P01B"#B#'4!3;;S):
M=2%-*3(@B8((D00<"","#MC-`[O>@#_M_;:V.G0,>]#!N3/7<@X*EURF403K
M3QV'PU1%7?E*I*8[EW'J0E,/I3QRC)P<`%?CS<-M8HUAIU%0\1Z58DV^/R@.
MBN7(X.ER9LR1U80#BIHE>B]2K88!]$U$W&#^23BB?*V>B=I(RJ/7$<U[:.^M
MU[>FS=:S#"FD);'<V+6J9MHC17WERQXZ=E.[4:MU#D;C::LL;X0B5C"40<)F
M0,8$'"P&]VNM(4NLK$Y;G<J:U$UL.'O'`,)[\JNJL<AG*:1$?P\UK5Z(U`W<
M6RI5`LA#S<\%MDX[<,R>L@X24)$A)4#ITXYR)3,MT*GY/QU8(^U46^UV*M54
ML46L"S&6@YIFD]8.TC![Y,QD50!1,X%424`Q#E*<IB@B-;155NJW*"M06ZME
M90M)VA23(C^X[",1A'0F@KJ2YT35PH5ARC>0%H4-A2H3!_O&T'`XQ]ISRQZX
MRX^Z]^TJW;_6$N_\\WX_'#SU'M?F;?XHYV\4/7VZ>=N?KF)<^SM_M4L._)[F
MSZ.Y7E<XT^H%3\,SXU,6?@1_V#3_``;WB7(T8^)5#UPJ#WPOVJO:#^4"L?3S
MCWC"\*O4#4?P*_\`;N0N'%W_`+!TUYPU_N$0U]Q>H8^#A!"M'?([*R6<FEHW
M'U+JQ4\W,&ZTSF+%$"T*1/,4<T1,H[N-4CVR8`&5&2"?B=-R!_2!$HB'^OE#
MUO?>%/%%5I6WIK43D[4HY675']B3L0LG_".XG]F=O0ZB[<7^$R+TVYJ?3C<K
MND%3S21^V`VK2!_B#ODCK[1TYAQ'=9$Z9UF[A$Z2J1U4'#==,R:J2J1S)+(+
MHJE*HDJDH42G(8`,4P"`@`AQK00H9DF8,)VI*VEY5`I<2?9!BT'*'<^RAG3M
MQ,-%LV_"5SE\:Y/Q_<,293<N2N98M#JL';(5UC^ZJ.#@ZDUH-.;0&(D.JBQF
MI#-G'7T22AJ!0Z"H+3K56K+5E::?IW$/-2D.T4I"@XC<,V4YTX"?2&TB--J>
M(]?>-%-Z0N^9UYBI;6R[/'LTI6CLUSQ.7.,BL3(%)P"8T3M./JAZK?JWX.^C
M&K\2_4WK)<//G_&KAX=*>J]M\PI_$HB2'(2)^.2V?`6";O-N[-=,*XEMUCD"
MMRO[!9\<4Z?FWI6C=)HT*[E96&=OW)6S1$B28'4-X$R%*'0``.2-/>+O2M!B
MEJJEMA.Q*'5I2)F9D`H`3./=B,J++9JQXU%724SKZI34MI"E&0D)DI),@`!C
MLCEN0\.:38EI-ER1DW#NM%&H=/BG,U9K79<8XVBX6&C&A/$JX=O',`0@"8>A
M$TR^)194Q4TRF.8I1D**YZJN-4BAH:FN=JW5!*4)==*E$\@"OPG8!B<(CJZU
M:2MM(Y75]);V:-I)4I:F6@D`<IR^P!M)P$S"141?<0=UKO38'K=9Q]1\:ZOL
MKXE#TJC1E2K5(1MF.<6,9[(DHYM$;#L(])]8LL2$$H51!<%5T(]RBSZCZ`1,
MTSM'<N'W"^K?J'GG[\69K<*U+*''2EL9"HF26@H8B0*@5;X4AJNM/$CBO1TU
M,PRQIX/94(2A#86VT%.'.`!-3N50,\0%!..4&'J/[J^L/V<<#?-!CWXO<4_Z
M07[_`%U9\<YX4.#]'-/?Z"B^(:\&#^ZOK#]G#`WS08]^+W#Z07[_`%U9\<YX
M4'T<T]_H*+XAKP8ZW6:K5Z5",ZU3:W`U*N1WI@CX"LP\?`PC$'"ZKIP#.*BF
M[1BU].Y6.H?P)E\2AS&'J(B/(Y^HJ*ITOU2UN/JVJ4HJ498"9)).&$2E/34]
M(R*>D;0TPG8E"0E(F9F0``$SCLVQ[[GQC[1P?9[7NB[5X!RIK[D=DF[JF3ZG
M(5YPL9,%%X>3,4KNO66/ZB`IRM8GVS:0:FZ^1=N7KU#J`R]AO-7I^[T]XHC*
MH8<"O=#8I)YE))2>8Q#:ALE'J.RU%DKA.GJ&RF?M5;4+'.A0"ASB,G*SP#JJ
M6:R55\X;.WM7L$W6WCMDH59DZ=P,FZBG+EFJ01*JU<+-#'3,`B!B"`\Z&T[R
M:FG;J$@A+B$J`.T!0!QY\8YHUE.JDJW*91!4VLIP,Q@=QWCGWQ)'2+:NVZ4[
M18EV/J)'#PU$L!26JOH+>A"W4":3&*N]55$WXH3RL"X5%L8X"5!\F@MTZI!R
M$U7IZGU38*BRU$AVJ.@KVCB<4*]A0$Y;4S&^+!HS4U3I+45->Z>9#2^FF<LZ
M#@M)QEBDD`F829*E,"-2O#^7<>9ZQE2\P8HL\=<,?9`@65BK,_&+IK(.F+Q/
MQ&07*0QC,Y*/7`[=VV4\*S5TDHBH4JA#%!!+E;JRT5SMMN#:FZQE92I)W$<G
M*",01@001@8Z,6RYT5XH&KG;G$NT3R`I*AR'<>0@X*!Q200<1"M_M6=[A6N-
M-/\`'(OFYIY]D/(=^7C2*$,\0@J]6XJ!*_51`?2)MW+^QBFF8>A3F2.`=1*/
M3>_N^TCJJ^Y5TCV*66VY[LRE*5+V`G'NCEA>?O&UC0MUMM\QY0MYQ8&^20A,
M_9S&7+(\D-1XTEHV>QQC^=AWB$A$35)JDM%/VQRJMGT;(P3!XQ>-U"B)5$'+
M58IR&`>@E,`\P"N;<9K7FG04NI=6"#M!"B"#W##%6]U#]`P\T0II;*%`C804
M@@CF(B$G=/TU:;RZ5Y8PVT9I+Y!CHX<A8>='`H*-,HTUL[?5UH14P?B6]G14
M<0[@WF!M('-YRARTZ`U,K2FJ*>YJ,J-2NS>'*TL@*/YADL<Z0(J7$32R-7Z4
MJ;6$SK4I[1G9^U0#E$R#+."6R=P5/:(S-,:8HOF6LK4C"5.@W:^2+_>8;',)
M`.D%4'3>T3,PE!@UDT3D!5D2*=J&,\$X!ZNDBH8W0"#QZ:ZY4ENMSMUJ5@43
M+2G%*W94IS3'+,;);21*.?=NM%9<KLU9Z=!-8Z\EL)D1TE*"1/"8Q.)(PVF-
M5G5/7BH:GZZXAUXHY"#`XLID77!?%2!%6=FBD,\LUF=D#J(/K-8G3I^MU$>B
MC@0\P!SGYJ"\U.H;U4WFJ_;5#I5+VJ=B4CF2D!([D=(=.6.FTW8Z:R4DNRIV
M@F<I9E;5K(Y5K*E'NQSKN)>30?='KY/_`*MYW\_R:63GMT7ZWVO_`)"G\:F(
M_7?J5=_^-J?%+C*D)^`7^*7^`.=!8YN*ZQ[L.]^RI"']W+:L.H=0SI6!$.H=
M0`<>1O01#S@`]!Z?O<53[P/]<H/-%>,,.%]W'U>KO.D_JF/W]^3;!YG'(V#N
MT=@*V,"W[/>3\=1F=Y5NY`S2K1D]88DM$H\JNDIX`=/7ZR<_)-?Y0K-DT(/D
M=B7GXX2:>3:J*KXBW=L^1TC#A8$L5%*5=HX!S";:3L)4KVL?7C#J4W:OI.&M
MG<'EM94-"H(."0I20TVK9M40XL`@@!&W,1%VN,.VQHQB['=)QS'ZLX%LC2E5
MF(KB=BN6(Z!9[;8#Q;-)LO.66P3%?>24O.2[@AG#E=50PG64-TZ%Z%#+:_7&
MK+A6NUJ[A6(4ZX594/.(0F9GE2D*`"1L`&X1J]OT!HZWT+5"BVT3B6FPG,XP
MTM:I#%2U*225*.))WF/NO[BFDOV/]8/F%Q;\5N>3Z6:I^<J_Y0[X<>SZ&Z0^
M:K=\F9\"#^XKI+]C_6#YA<6_%;A]+-4_.5?\H=\.#Z&Z0^:K=\F9\"$$N]WH
M;$Z+[D2C/'\<2-PEG*->93Q;&MTQ(SJAW$HJTNF/VG^:5E59PY56)`_D8M^U
M2$1%,PBW_"K5SFK--)56*S72D4&G2=J\)H</.M/6Y5I4=D)7Q@T6UI#5!\A2
M$VFK3VK0&Q$S);8YD*V<B"B<S,Q!33/::\:7[*XLV,H1U5I"A3Z1Y^"*J*2%
MOH\GT872GO/*!!1GH%55-(YNOH'0(KE]^D40MFJ-/TNJ+'466KZCJ.BK>A8Q
M0L>Y5(\XF-ABFZ0U+6:3O]/>Z,F;2QF3N6@X+0>9221/&1(4,0(U-\-Y=H.?
M,5T',V+IUO9<?Y)K$9;*M,-C%Z.(V40!4$'213'%G)QZ_C;/&QQ!5JZ1424`
M#D,`(%<[=66BX/6RO045C#A0L<XY.4$8@[""",#'1NUW.CO-N9NEO6%T;[86
MD\QW$;E`S"@<0H$'$0F#[52(?WG=6PZAU#`]G$0ZAU`!R"Y`!$/.`")1Z?N]
M.,[]W[^A5_G:?%B%2^\A_6K?YJ?&+A8:I_ULJON?TGKWG\@?\89><?<YO-3_
M`"[GN%?B,+M0_P`XW[H1K]MO]F;_`.@2_FR\YN*ZQ[L=0T]4=R*SN[+H+$=P
M34VT8ZCVS)#,=&%S?<%6!T8B'J5YCF:A5:V[>&#JC`WN-`\:[`1]&FHH@Y,`
MF;$#EZX>:O<T=J)NM62;:[)M](QF@GK`>V;/2&\B:>^,4'B5HQK6VFG:!`'I
M-J;C"CATP,4$^U<'1.X'*L@Y1&9/,0\M7I>6K\_&O86>@9.0A)R'DD#M9&(F
M(EVLPE(M^U5`JC9['OFZB2J9@`2*$$!\W'L:=;?:2^RH*96D*2H8@@B8(.\$
M8@QSUJ&':5]=.^DI>0HI4")$$&1!!Q!&\'$;X:7]G3[G:>*K<CH;F^QIM<<Y
M"F7,AK[89=QX6]1R/+N`6D\;+/%U`3:0-^<F,YC"#T(C-BHD`"9^'@P#C3H,
MU].=76I$ZUE(%0D;5MC8Y+>IL8*Y42/>8LAP*XB"@J!HZ\.`4;RITZE=XXK:
MW/8$N'J[).<I<,G>>*O#=1EP]UPQ3]RG=P2&*8`V%O)1$H@8/$FY0(<O4.H>
M(ARB`A[@ATX_'#SU'M?F;?XHYV<3R#KVZ2_U;GZZHEU[.X8H=U+#8"(`)L?9
MM*4!$`$QOT<RY_"7KYS>$@CT_<`>5SC1Z@5/PS/C4Q:.!!'V@TWP;WB7(T9.
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M&TNM@=_O6@=;%2>G,+2H7_D%P$!`035`0$!*8H@4P"4Q1`!*8HAT$!\H#QHX
M4IM)2\E*L"%#\<:RVG'U0]5OU;\'?1C5^<[]3>LEP\^?\:N.EFE/5>V^84_B
M41)#D)$_'J9Y"6=0<RV@'J$;.N(F10A9%TB#ELPEE6:R<:]<-Q*<%T&KPQ#G
M()1`Q2B'0>O/HR6TNI4\"ID*&8#`D3Q`[HCY/!U3*TL$)>*3E)Q`5+`D;P#C
M"<>\?:IWWR8PB[+OSW>-;HRI*2P%@&>8+7)XFQ<E."0OA+`U=R2HT8)<$P#P
MF3;&=>'_`#N,KI3B!I&A6IC2.G*U52$](LH#KN7\I0*W)3Y3*%AUCPZU=<4!
M_5^I*-%(5'*'W2RU/\E)0AO-+VJ09;8@;C_LSP/Y\5$<6=XCMU_I*"PQ8T3\
MP,\,AO'YU`Z3&%_-,*[9QG1G_70+ZL#3_6!4Z`3R\M];Q-?\D<](::O7D.0]
MIVE.<F272SYDY<LML\);8H]!PKHA6-FV:GLGE^<=GV=6GM,\QER9>EFG*67&
M<I8PSEJ=JOWD,29.QLKGWN#8KS7@NOR2@WNG+XQ05O=G@RQ+]LV8M+R]IK*:
M(])**-UCN%G@JG*D8#'-XA`<'U#?^&MQH7Q:+/44MU6GWM?:$(2J8,R@.%,I
M3$@F7-##:;T]Q,MM<R;S>&:JU(5TT9`5J3+9G+(7/G+D^4G9%V7,OC58.$$?
ME>D=*,G:;%8C=ZHU<$9N%">D30=&2.5NLHF(&`Y$E1`PAT'J`<_22D*!6)IG
MCW(_*PHH(09+D9'GW0N!FC1#OGY5I]@@+UW4,.5BENXV1+83TO'R^+3?`7JZ
MPR!9"TU.H0LXPCP8>,'!B/4B>B\7C'P]>;7:]6<*;?4H>I+!4N5(4,N=?:]+
M=)*W%))GLZ)QV1AMUTAQ9N-*MFKU!3MTI00O(GLL)=(E3;"5`2G/I2EMG"^P
M]F?$O4>O>([7O7J/7KGBM=>O7R]>MGZ]>OGYLGVFW/ZM7[Y.OP8PT\*K+/'4
M]@GYVW'C[F?$G_>'[7OS\5GXS\/M-N?U:OWR=?@Q_/LJLGUGT_\`*VXLJT>[
M5>_^-(25GM"N[QKI)449DQ)YIAZT2.6,7GL)$^JP2M?11N%(2G!1-^,,*!'1
MB]/$;H`=*-JOB!I"N=2UJ[3E:FKR]$O(#3N7F5-#F6?/*<:)H_AUK"WLJ=T=
MJ2C71YAF[%TO-9N=(0MO-+>1.4N:.(;K]IC/-^S$6V;W]WO22/S%*UQDI&,L
MV7]IC>6;TQ-[()QZ=7ITLXK+6)J@20.O1@Q9IM3N?3&$3*BH/)72W$.U4=L\
MGTEIRZ*MJ5F98:+HSR$\RQF)7*4\RB92W2B&U?PUN===!4ZRU+:TW-2!(/OI
M:5DF994*2@!,\TLJ0F>;?.+*],-"N[KA/'^+HO"'=&P#?-;4#UR1K,<A5?TL
MUI[CPK]JX<1N/+C,UR?40@7T011)B#.0]20`X>A`A0\E&U/J[AU=*Q]RZV&K
M9O9S!1*NQ4');7$)6GI`XG,G,=\XT'2>CN(UIHJ=NUW^E>L0`*`)/(*-H[-:
MF5=&6`"%A,MDML,V\PN-[A=;7G3'0VE=X;+6T=/VSU>N%OMRMK#'.L->RICR
M3R?1M@9Y%RUS/*C4V-A<22KEHU82ZJ3%)H#N/6D7GI2I@V(([1>=3ZNJN&U/
M8:FW5[=*V$=I5*:<#2Z=.+(SE,I&:`5$R4$ID3F,8?8]*Z*I.)M3J"DN5O=K
M7"YV=*EYHNMU"A)XY`K-,>^G+*8SF8&0$L4\Q>-PA;;=[2/NU9JI&<83*'<Q
MUUQMJI-O+?)3<7+4=ICF/@\2GE7CYC!7_(3.LQ+DD+&5\44))5:13;N2)G!<
MQTSF`VVZ5U3P\M=52NT%CK']0("`DA9<*G9`%3;961F*IE,DS&$@"(PO5VD^
M(MUHZMFOOM(QIY965!02TE+4R0E;@920D"05-9!V*)&U?7[F?$G_`'A^UY\_
M%9^,_-D^TVY_5J_?)U^#&&?959/K/I_Y6W%B&C':QW:QY$963[?G=WU0?PEG
M3AXC*IL%6%')[!H]]7D#5]S)*Q36V(5.S`R4=`S>)"T?"CX_1G$I?>TK5FO]
M+UKM.=8:<N"76\Q:[='9$C#-*91G3.4TF:9RF(ONC>'>IZ!FH&BM26];#F4.
M^3NAT#K99Y6UY%=:2AE5MD8AN[[,Y_TN+>O=XC0;]/(Y`**XN\\#^EW]*8SA
M!)Z7TUG_`#Q"_?G)X?"`_P"\/7>@!^,Z<LZ>)O\`ZWH::N_HCL=U/[SV67W.
M3L\OYN7FBJKX5H]*YG-3VCTUVV^K';=KF_3[3/\`G9N>&D=)-;NZ_AO)E?4V
MPWEQGL+@Z*KDY'/JBQQRW87R0F56*:%;DEKNM4XJ6=DC711.N*[HZC@!]^)Q
M$1Y@6J;WP^N="L:>M3]'=5+20LN$M@3Z0R9U)$Q@))`&Z4,5I.Q<0[76H^D5
MU9K+6E)!0$#.3(A/3[)*C(R,RLDXSG.8MZYG,:5$2=RZ+MYD'%L3"Z6YLHF!
MLJ(72+D9>XY"I;6]0KVDHQ4VC*P#>(=Q$TDA)/)9RQ6(X]"`D3;G+X@\?EL6
MF:O3E'7J=U/2NU=`6B$H;64$+FF2B0I,P$A0E/:0=T5O4]'J2MH$-:7JFJ2O
M#H*EK0%@MY5`I`*%@',4&>78",)PK%O]VN]N<MVZBV/N%=V_2N#L",3.,\9L
M,O345AF.)$@ZCE;*:FUQ=O3HYX`NC,_7W""*RO7T!53]`3`-^T=KW3MMIG6-
M&Z=N:VBI)=+*5/&<CESJFLC">4$@;9#;"ZZWX>W^Z5++^M]26MMT)4&@^ZA@
M99C-D3V;:3C+,0)[)G9%?_W,^)/^\/VO?GXK/QGY<?M-N?U:OWR=?@Q1OLJL
MGUGT_P#*VXMTT/[;W<SPKC=TIHQW8=7[/A:7G)0X-::T)G#%:5F2.1.</!'=
MQ-O@829]-X?7B,%6YCJ]#+E,?H/,XU=K;0UTK@-5Z>KF[HE`Q7[P[E[W-)2%
M*'M<TQR1J>C-"ZZM-!__`".HJ%RTJ4?V:@^UFWY9M.)2>7+(GOIX1%K>?M2[
M$Y,R_'V_?GN[:01.67]4:)UN/S'<H[%+QO1V\E)$:EJ5,?GJC)C6OAH7G51F
MT!)9YZ83G.KXQY/Z2X@V>@MIIM(:<NBK>'#F++9=&>0GG6"LE67+UE3`E+"4
M5O6?#B[7&YIJM::EM2+@6QE#[R63V<U2R(*$`)GFZJ0"<V^<0Q+V9\3"8H$[
MQ':_\8F*!/!GFM@?Q]0\'@$MG\0'\73IT\O7S<M!XFW.6.FK]+S=?@Q44\*K
M*""G4]@S>=MPU7IOK!W>,0Y!Q27/F_&(,XZ\59LX:V:H-,9MS7JTP@5J08UU
M-OD%U4V<PY79RRC-R=TN\.LX21,!U#B<>J^ZEOW#FY4=1Z(M%12WEPS2LN'(
MA68%7O8<*1,9A()D"<`)0R6E]/\`$BV5=,+O>&*NS-X*1D!6M.0A(#A92LR.
M4YBLD@8DSBZ?F81JD)J=U[MIZ@[#;A7G+&,.XIHEKE;+``-<ZXKRSF>C0\W'
MY<B%3,)F;"&96=!]!R<VP20&59O$$EPDDE7!A,=P<"LSP\USJ6S:;:M]=9;M
M6TR,6'66'%)+)Q2G,4R4$F>4@D92!L2)JQQ)T#I*^:F=N-'?+10U:_V[3U2V
MA0=!(4<LR4E4AF20#GSJ,RK"MYKV9\6BZ:@R[Q';%]=%RW!EZGGFO`\]<%8G
MJGJ@H6@%P=>L>'T?@]_X^GA\O3EW5Q-N.4Y]-7W)+&=.J4M\^CLBA-\*K0'`
M6M3V'M)X2JT3GS0Q#3-*._14:'%4F![I&$)*#CXI&/B9R?Q(C;[5\&@W*FT.
M>Y3U%DIJ66(W\/@=.EG"YO(85##Y>8M5:HX2U%6JJ=L-4EU2IE*72A,YX]!+
MH2.X`!S1NU)I3B[342:1F_TZF@D!*E(2M4I8=-=.I2NZ5$\\4)91[.$8\R5?
MW>8^\-VZ2Y:=W&Q.<F%ON;8MA=RWMQ*NEK06VL9BP-I1E80F#J^MHN$TU4EO
M$4Q2B'0-?M_$MU-"RFV:;O7HX-)#79TY*.SD,F0I!!3EE(@R(C%+GPLI'+B^
MN[:GL@N9=47>TJDA?:9CGSA0"@K-/,#C.<\8^_UB[0MRK&<Z%8M2N\#H*YV!
MAGLA(4!OB7*L;;[TLLA$/S3:4;5XB3FW4ZP/7O6@?MCM'#=1CZ7TQ!2\7/'?
MN(]/46EYG46F[N+.H`.%YDH;ZPRS4K*$G-+*9@YI2,Y1[M.<,7*:\,OZ9U-9
MU7I));#-2E;D\IS20E*BKHYLPRD%,\P*9Q>^YU6[_P"Y8J,1[F.MJ'I$11%X
MUUZ@47Y`$OA%5)Q^CHQ2+^[X@+Y!YD:;_P`(4KS^@ZTX["^J7CHVA6G>,*D9
M/3M(#*4PRW/N_P`M%!NPO9VL<KF6\2>T/>%T+)GF1DF[S(!,PYE;PF122#E@
MT4CRSD/8YN.EHHA8DS<&;<4$4DFGHBHD*D!`YK]FXE,MVMINPZ;NYM"4D-]B
MP5-R!,\I2"DXSF9DDSF9SC%+]PN4]=G7=0ZFM`O*E3<#U2$N3($LR5@*&$I`
MC!,@,)0P/IKIYW@\(V7#+2_]Q;$^9M<*Q)P*UDJ;RB'M%MM..T&WO(:"R1.5
M=6PJ"Y9F2]6=K22A@2`.BGAZ<QS4VI.&]T8JE4EEJ*:].)5E6%Y$(<.]3:5Y
M<#M`1[$;?I;3/$FTNTR*V],55E;*)H*0M2FQ+`.*9SF:=A[3#"1D)1?+S)8U
M^#A!!P@A'_O,]O\`TVR9E*:S7I9MCI+6,HSMFE8S/6`++M1@;'3)*V%7>$F+
MQ`FLEYC6%8GRRB1D9Z'<>K@HY,+A(I5_6$U&IX9:QU-06Y-KU-;KHY0(;!IZ
MA-+4.')(20K*V2I,L6UB>'1.&4A2.*.BM)7"[>EM+W.TM7!3I%13JJZ9OIS.
M9:0MU(2J8DX@RZ72&.80X-JM#N*[K!KA7W;N(?NX+`N'X=T^K\S'6*!>N(S'
MM=9+NX2P0[AW$SL0X40$[9XU55;.D1*HF<Q#%$5MU`ZEZ_5SR0H)76/*`4DI
M4`7%&2DF121O20"#@<89W3;2F-.T#"BA2D43"24J"DDAI(FE224J2=R@2",0
)91WKD1$U'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
